Surgical treatment of ovarian cancer, from DNA to robotic surgery.
Seance of wednesday 19 november 2025 (Communications libres)
DOI number : 10.26299/vt91-2d79/emem.2025.47.03
Abstract
Ovarian cancer is often diagnosed at an advanced stage. Patients now benefit from significant advances in medical oncology with the development of new systemic and maintenance treatments. Surgery is also evolving with the rise of robotic surgery. One of the current challenges is to identify and select patients who are eligible for these innovations.
The advent of precision medicine, particularly through tools such as circulating tumor DNA (ctDNA), could change treatment patterns. Molecular biology, now indispensable, makes it possible to tailor therapeutic strategies to each patient's tumor profile. ctDNA could offer a non-invasive alternative for monitoring, assessing residual disease after treatment and early detection of recurrence, thereby reducing the need for invasive diagnostic procedures.
Minimally invasive surgery for cytoreduction of advanced ovarian cancer is attracting growing interest. This approach would allow complete cytoreduction while reducing the morbidity of the procedure and speeding up patient recovery. However, its success depends on rigorous patient selection and multidisciplinary assessment within specialist centers. Studies are being conducted that will clarify the place and safety of this approach, moving towards comprehensive, personalized and less invasive care, while maintaining the requirement for complete cytoreduction, whose prognostic impact remains paramount.
The advent of precision medicine, particularly through tools such as circulating tumor DNA (ctDNA), could change treatment patterns. Molecular biology, now indispensable, makes it possible to tailor therapeutic strategies to each patient's tumor profile. ctDNA could offer a non-invasive alternative for monitoring, assessing residual disease after treatment and early detection of recurrence, thereby reducing the need for invasive diagnostic procedures.
Minimally invasive surgery for cytoreduction of advanced ovarian cancer is attracting growing interest. This approach would allow complete cytoreduction while reducing the morbidity of the procedure and speeding up patient recovery. However, its success depends on rigorous patient selection and multidisciplinary assessment within specialist centers. Studies are being conducted that will clarify the place and safety of this approach, moving towards comprehensive, personalized and less invasive care, while maintaining the requirement for complete cytoreduction, whose prognostic impact remains paramount.